Diagnostic Tests

LES ASSOCIATIONS CLINIQUES

Complement Panel 6 is designed to evaluate systemic activation of the complement system through any of the three (classical, lectin, or alternative) pathways by measuring levels of the terminal complement complex (sC5b-9), formerly referred to as the membrane attack complex (MAC) which may underlie thrombotic, inflammatory, or autoimmune diseases. Elevated sC5b-9 reflects active complement consumption and terminal pathway engagement, which is seen in a range of immune-mediated and inflammatory disorders. Clinical conditions associated with complement activation include atypical hemolytic uremic syndrome (aHUS), systemic lupus erythematosus (SLE), antiphospholipid syndrome, transplant rejection, and certain infections or sepsis, among others. Monitoring sC5b-9 levels can aid in diagnosing complement-mediated diseases, assessing disease activity, and guiding treatment strategies, particularly the use of C5 inhibitors such as eculizumab or ravulizumab.